Concept

Over the past 25 years in the Western world, scientific and technological advances in the treatment of disease have dramatically outpaced changes in the financial and social structure of healthcare delivery and innovation. This disparity has stimulated intensive, important and interesting debate between medical professionals, companies and government regulators.

In its most basic form, the emerging debate has considered the issue of each person's right to new forms of healthcare. How does a society decide which new medicines, technologies and tests should become available to all of its citizens? How do these national decisions fit into and affect a global pattern of healthcare delivery? The current answers, arrived at almost by default, have fragmented markets, harmed innovators and mystified consumers as to the value of those technologies and the wisdom of spending money on healthcare technologies in general.

Despite the importance of the questions by themselves, there exists today no journal which covers the interdisciplinary and dynamic world of the global medical community from the perspective of the role of social and scientific innovation.

Content

Each issue of Innovation in Medicine contains quarterly columns from leading members of the major healthcare sectors (governmental, regulatory, academic, NGO, pharmaceutical, medical technology, insurance), special contributions from leading social and scientific innovators, a focus section on one medical institution worldwide, and a special description of a medical innovation from history.

The journal serves as a communication platform between world-leading scientists, government leaders in healthcare, CEOs and top executives of pharmaceutical, biotechnology and medical equipment and device corporations, as well as world-renowned academics and physicians; It furthermore complements the annual debate about innovation held at the Global Medical Forum conferences.
To subscribe please contact the Foundation or visit www.karger.com/iim